Dose-Related Control of Allergic Rhinitis Symptoms by a H1-Receptor Antagonist
| Autor: | I Andresen, G Nirnberger, Siegfried Jäger, Friedrich Horak, J M Vix, Uwe Berger, D Rehn |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Allergy
Dimethindene business.industry Immunology Provocation test Antagonist General Medicine Histamine H1 receptor medicine.disease Placebo chemistry.chemical_compound Dose–response relationship chemistry Dimetindene Anesthesia otorhinolaryngologic diseases medicine Immunology and Allergy business |
| Zdroj: | International Archives of Allergy and Immunology. 103:298-302 |
| ISSN: | 1423-0097 1018-2438 |
| DOI: | 10.1159/000236643 |
| Popis: | The aim of the study was to evaluate the efficacy and duration of two doses of dimethindene, in a sustained release pellet formulation, with a standardized grass pollen provocation model (Vienna Challenge Chamber, VCC). The study of 12 grass pollen-allergic volunteers (verified by case history, skin prick test and RAST) was carried out in a placebo-controlled, double-blind, cross-over design. 12 h before a 4-hour continuous challenge with permanent 1,000 Dactylis grass pollen/m3 of air in the VCC, 4 or 8 mg of dimethindene (Fenistil pellets) or an identically appearing placebo was administered in three sessions. Nasal flow and resistance, nasal secretion and subjective symptoms were recorded at 15-min intervals during this long-term challenge under reproducible conditions. In comparison to placebo, dimethindene leads to a statistically significant reduction (p < 0.05) in nasal response and clinical symptoms for at least 16 h after treatment. The efficacy of 8 mg dimethindene was superior to that of 4 mg dimethindene; however, the differences between both active treatments were not statistically significant. Therefore 4 mg dimethindene once a day is adequate for usual pollinotic disease conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|